A groundbreaking exploration conducted by researchers at Oregon Health & Science University (OHSU) brought to light a new mechanism of cell death in Alzheimer’s disease and vascular dementia, opening the way to new perspectives in research and possible therapeutic approaches.
This important study, recently presented in the prestigious Annals of Neurology, points to ferroptosis – a form of cell death caused by the accumulation of iron inside cells – as the culprit behind the death of microglial cells in the brain.
Understanding microglia and their role in neurodegeneration
Microglia, the immune system cells found in the brain, are vital in maintaining a healthy neural environment by cleaning up cellular debris, especially when myelin—the protective sheath that surrounds nerve fibers—is damaged. However, this recent research reveals a surprising revelation: the very act of clearing iron-rich myelin leads to the destruction of microglia through ferroptosis, reshaping our understanding of the progression of Alzheimer’s and vascular dementia.
Innovative techniques reveal new realities
Led by senior author and esteemed neuroscientist Stephen Back, MD, Ph., the OHSU research team used innovative techniques, including examining postmortem human brain tissue from dementia patients. Dr. Buck, with a strong background in myelin studies, emphasized the ground-breaking nature of the findings, shedding light on the complex relationship between neurodegeneration and myelin deterioration.
The pivotal discovery was made possible by the cutting-edge methodology spearheaded by lead author Philip Adeniyi, Ph.D., a postdoctoral researcher in the lab of Drs. Back. This technique focused on the role of microglia in the white matter regions of the brain of patients with Alzheimer’s disease and vascular dementia.
Dr. Buck acknowledged the significance of the findings, stating, “We have missed an important form of cell death in Alzheimer’s disease and vascular dementia. It’s just amazing that we missed this until now.”
Implications and future directions
The revelation has transformative implications for our understanding of Alzheimer’s and vascular dementia. Microglial degeneration, a key observation made by co-author Kiera Degener-O’Brien, MD, hints at iron toxicity from myelin fragments causing this degeneration. The consequences are profound: these immune system cells succumb while fulfilling their protective roles, potentially leading to cognitive decline in patients.
Recognizing the potential impact, Dr. Back expects increased interest from the pharmaceutical industry, anticipating the development of compounds that target microglial degeneration.
The origin of this degenerative cycle is likely to be traced to repeated episodes of reduced blood flow and reduced oxygen supply to the brain, with factors such as acute stroke or chronic conditions such as hypertension and diabetes possibly contributing.
Dr. Buck concluded with a sobering thought: “Dementia is a process that goes on for years and years. We have to deal with it from the first days to have an impact so that it doesn’t get out of hand.”
As the field teeters on the brink of this breakthrough, dementia research is gaining renewed momentum. This discovery, which focuses on the central role of ferroptosis, opens up new opportunities for scientists, researchers and pharmaceutical innovators, shaping the future landscape of dementia care and treatment. Only time will reveal the full extent of how this new knowledge will affect the field.
